Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant melanoma within the conjunctiva of the eye.
Biomarker and diagnostic research for malignant conjunctival melanoma has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
3 clinical trials registered, 1 recruiting. Interventions under study include procedural interventions, drug therapy, and biologic therapy. Pipeline includes 2 PHASE1. Research is primarily sponsored by academic and government institutions.
33 publications have been identified in PubMed for malignant conjunctival melanoma. Research spans Case Report / Case Series (48%), Review / Meta-Analysis (12%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 16 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:54 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 4 | 12% |
Clinical study results | 4 | 12% |
Disease patterns and progression | 4 | 12% |
Laboratory research | 3 | 9% |
Testing and diagnosis research | 2 | 6% |
Concha-Tuero AC (2026). [PMID: 41924201](https://pubmed.ncbi.nlm.nih.gov/41924201/). *Clin Ophthalmol*. [Epidemiology / Natural History]
Kagaya R (2026). [PMID: 41697719](https://pubmed.ncbi.nlm.nih.gov/41697719/). *Clinical nuclear medicine*. [Clinical Trial Publication]
Sezgin M (2026). [PMID: 41617257](https://pubmed.ncbi.nlm.nih.gov/41617257/). *BMJ open ophthalmology*. [Epidemiology / Natural History]
Liu H (2026). [PMID: 41820066](https://pubmed.ncbi.nlm.nih.gov/41820066/). *[Zhonghua yan ke za zhi] Chinese journal of ophthalmology*. [Case Report / Case Series]
Saray S (2025). [PMID: 37499639](https://pubmed.ncbi.nlm.nih.gov/37499639/). *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. [Case Report / Case Series]
Lenz JA (2025). [PMID: 41381219](https://pubmed.ncbi.nlm.nih.gov/41381219/). *Journal for immunotherapy of cancer*. [Case Report / Case Series]
Schilcher AV (2025). [PMID: 39775873](https://pubmed.ncbi.nlm.nih.gov/39775873/). *Die Ophthalmologie*. [Epidemiology / Natural History]
Xu H (2025). [PMID: 39898362](https://pubmed.ncbi.nlm.nih.gov/39898362/). *Advances in ophthalmology practice and research*. [Case Report / Case Series]
Romani A (2025). [PMID: 40406621](https://pubmed.ncbi.nlm.nih.gov/40406621/). *Frontiers in molecular biosciences*. [Review / Meta-Analysis]
Alhamood M (2025). [PMID: 40685334](https://pubmed.ncbi.nlm.nih.gov/40685334/). *Journal of medical case reports*. [Case Report / Case Series]
AI-curated news mentioning malignant conjunctival melanoma
Updated Jul 23, 2026
A case report highlights cytokine release syndrome triggered by the combination therapy of nivolumab and ipilimumab in a patient with lower palpebral conjunctival melanoma. This finding contributes to the understanding of adverse effects associated with immunotherapy in rare melanoma cases.
A study published on PubMed details the clinicopathological profile of conjunctival melanoma at a referral ophthalmology center in Peru. This research contributes to the understanding of this rare ocular malignancy, although specific findings and implications were not highlighted.